Clinical trial
A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.
NCT07593820
Study timeline
Study start (actual)2026-04-29Date precision: day
Registry last updated2026-05-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Metastatic Gastric Cancerunresolved
Metastatic Breast Cancerunresolved
Endometrial Cancer Metastaticunresolved
Interventions
p95HER2.CAR-TECH2MeBIOLOGICAL
Sponsors & collaborators
Vall d'Hebron Institute of Oncologylead sponsor
Banc de Sang i Teixitscollaborator
Consorci Mar Parc de Salut de Barcelonacollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07593820 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.